کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8735095 | 1591019 | 2017 | 4 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Current status of art mobilization in Myeloma
ترجمه فارسی عنوان
وضعیت فعلی بسیج هنر در میلوما
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
پیوند سلول هماتوپوئیت، بسیج سلول پیش گیاهی هماتوپوئیت، میلوما چندگانه،
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
هماتولوژی
چکیده انگلیسی
Multiple myeloma is the leading indication of autologous hematopoietic cell transplantation (AHCT) worldwide. Hematopoietic progenitor cell mobilization (HPCM) is the first step of a successful AHCT. A minimum of 2Â ÃÂ 106 CD34+ cells/kg are needed for successful engraftment. Growth factors have been used both alone or in combination with chemotherapy for HPCM of patients with myeloma. Mobilization failures result in delays in AHCT and increased cost and resource utility. Strategies to mobilize progenitor cells were mainly chemotherapy and growth factor or growth factor-only mobilization until the advent of plerixafor. Plerixafor is successfully integrated into both growth factor-only and cyclophosphamide and growth factor mobilization strategies with significantly reducing the mobilization failure rate in myeloma patients. The best strategy to mobilize progenitor cells with the highest yield and lowest toxicity and cost in patients with multiple myeloma has not yet been determined. This review aims to summarize the current status of art mobilization in myeloma comparing the pros and cons of different mobilization strategies.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Transfusion and Apheresis Science - Volume 56, Issue 6, December 2017, Pages 850-853
Journal: Transfusion and Apheresis Science - Volume 56, Issue 6, December 2017, Pages 850-853
نویسندگان
Omur Gokmen Sevindik, Serdal Korkmaz, Fevzi Altuntas,